Contributions from CHE researchers

16-19 November 2020

#ISPOREurope

Methods to address limited evidence available from pharmaceutical regulatory processes

Professor Steve Palmer will be speaking at and Professor Mark Sculpher chairing the Plenary Session, ‘Much Ado About Little- Dealing with Limited RCT Evidence for Early HTA and Reimbursement Decisions’ on Wednesday 18 November, 13:00-14:30 CET and then speaking in the Educational Symposium, Bridging the Gap- Pathways for Regulatory and Health Technology Assessment of Histology Independent Therapies from 15:00-16:30 CET.

How should we approach modelling of complex clinical contexts?

Rita Faria will be presenting in an On Demand Cost-Effectiveness Modelling of Complex Pathways workshop, which will be available in the days leading up to the conference through to 31 December: ‘Lessons From a Cost-effectiveness Analysis of Screening for Familial Hypercholesterolaemia to the Design of Models of Complex Pathways’.

Professor Mark Sculpher will chair the Spotlight Session, ‘Novel Methods for Modeling Treatment Sequencing’ on Thursday 19 November, 14:30-15:45 CET.

How is the value of new pharmaceuticals shared between patients and manufacturers?

Beth Woods is on the Research Review Committee and will also be presenting in an Issue Panel on 17 November 17:00-18:00 CET, How Should Pharmaceutical Companies and Patients Served By Health Systems Share the Value Generated By New Medicines.

What approaches should be taken to update methods guidelines for HTA bodies?

Dr Marta Soares will be speaking in and Professor Mark Sculpher chairing the workshop ‘Methodological and Normative Issues Arising in Recently Updated National Guidelines for Economic Evaluation’ on Tuesday 17 November, 17:00-18:00 CET.

Are rare diseases special?

Professor Mike Drummond will be chairing an On Demand discussion, ‘Do HTAs Need Special Approaches for Patient-Reported Outcomes in Rare Diseases?’.

Is value portable between jurisdictions?

Mike will be panellist on another On Demand discussion, ‘Is Value Portable? A Conversation about Transferability of Value Assessments Between Settings’.

Can Europe afford gene therapies?

Mike will also be speaking live in the Educational Symposium on November 17, 15:00-16:30 CET ‘Gene Therapies: Is Europe Ready to Value and Reimburse the Next Medical Frontier?’